Drug intelligence / Profile preview

GOVX-E301

Development stage: Preclinical
Lead developer: GeoVax Labs
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GOVX-E301 is an investigational, single-dose Ebola vaccine developed by GeoVax Labs using the company’s modified vaccinia Ankara (MVA) viral vector platform to express non-infectious Ebola virus‑like particles displaying the Zaire Ebola virus (ZEBOV) glycoprotein, with the goal of rapidly inducing protective humoral and cellular immunity for epidemic response against the Zaire strain responsible for the 2014 West Africa outbreak.[1][3][5] The vaccine is being advanced in collaboration with U.S. government partners (including NIAID/NIH and CDC) as part of a broader filovirus vaccine program but has not reached late-stage clinical development or approval.[4][5][9]

Beyond the preview

Go deeper on GOVX-E301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GOVX-E301.

Explore the full profile